[HTML][HTML] Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens
…, R Yorsaeng, P Nilyanimit, R Aeemjinda… - International Journal of …, 2023 - Elsevier
Objectives To report the safety and immunogenicity profile of a protein subunit vaccine (Covovax
TM ) given as a third (booster) dose to individuals primed with different primary vaccine …
TM ) given as a third (booster) dose to individuals primed with different primary vaccine …
[HTML][HTML] Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: A cross-sectional survey from October 2022 to …
…, L Wongsrisang, T Thongmee, R Aeemjinda… - Scientific Reports, 2023 - nature.com
Seroprevalence studies on SARS-CoV-2 are essential for estimating actual prevalence rates
of infection and vaccination in communities. This study evaluated infection rates based on …
of infection and vaccination in communities. This study evaluated infection rates based on …
[HTML][HTML] SARS-CoV-2 antibody dynamics after COVID-19 vaccination and infection: A real-world cross-sectional analysis
…, S Assawakosri, P Nilyanimit, R Aeemjinda… - Vaccines, 2023 - mdpi.com
The Coronavirus disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2), continues to surge despite the widespread use of …
Syndrome Coronavirus 2 (SARS-CoV-2), continues to surge despite the widespread use of …
Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine …
…, S Klinfueng, T Thongmee, R Aeemjinda… - Journal of Medical …, 2023 - Wiley Online Library
To compare the reactogenicity and immunogenicity between the two‐dose mRNA COVID‐19
vaccine regimen and one or two doses of inactivated vaccine followed by an mRNA …
vaccine regimen and one or two doses of inactivated vaccine followed by an mRNA …
[HTML][HTML] The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: Safety and immunogenicity to Omicron BA. 4/BA. 5
…, R Yorsaeng, P Nilyanimit, R Aeemjinda… - Vaccines, 2023 - mdpi.com
The aim of this study is to investigate the reactogenicity and immunogenicity of the fourth dose
using monovalent mRNA vaccines after different three-dose regimens and to compare the …
using monovalent mRNA vaccines after different three-dose regimens and to compare the …
[HTML][HTML] Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year
…, R Yorsaeng, L Wongsrisang, R Aeemjinda… - Vaccines, 2023 - mdpi.com
This study investigated the impact of hybrid immunity on antibody responses in the participants
who received two to seven doses of the COVID-19 vaccine. The study was conducted …
who received two to seven doses of the COVID-19 vaccine. The study was conducted …
Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated followed by an mRNA vaccine in children aged 5 …
…, S Klinfueng, T Thongmee, R Aeemjinda… - medRxiv, 2022 - medrxiv.org
Objective To compare the reactogenicity and immunogenicity between the two-dose mRNA
COVID-19 vaccine regimen and one or two doses of inactivated vaccine followed by an …
COVID-19 vaccine regimen and one or two doses of inactivated vaccine followed by an …
